Beyond Acute COVID-19: Investigating the Incidence of Subacute Thyroiditis in Long COVID-19 in Korea

다국어 초록 (Multilingual Abstract)

Background: The correlation between acute coronavirus disease 2019 (COVID-19) and subacute thyroiditis (SAT) has not been clearly investigated in “long COVID” patients. We aimed to investigate the incidence of SAT during convalescence and after the acute phase of COVID-19, comparing with that of the general population.
Methods: Data from a total of 422,779 COVID-19 patients and a control group of 2,113,895 individuals were analyzed. The index date was defined as the date 3 months after confirmation of COVID-19. The incidence rate (IR) of SAT and hazard ratios (HRs) were calculated per 100,000 persons. Subgroup analysis included analysis of HRs 90–179 and 180 days post-COVID-19 diagnosis; and additional analysis was conducted according to hospitalization status, sex, and age group.
Results: The IR of SAT was 17.28 per 100,000 persons (95% confidence interval [CI], 12.56 to 23.20) in the COVID-19 group and 8.63 (95% CI, 6.37 to 11.45) in the control group. The HR of COVID-19 patients was 1.76 (95% CI, 1.01 to 3.06; P=0.045). The HR of SAT was 1.39 (95% CI, 0.82 to 2.34; P=0.220) up to 6 months after the index date and 2.30 (95% CI, 1.60 to 3.30; P<0.001) beyond 6 months. The HR for SAT among COVID-19 patients was 2.00 (95% CI, 1.41 to 2.83) in hospitalized patients and 1.76 (95% CI, 1.01 to 3.06) in non-hospitalized patients compared to the control group. The IR of SAT was 27.09 (95% CI, 20.04 to 35.82) for females and 6.47 (95% CI, 3.34 to 11.30) for males. In the 19 to 64 age group, the IR of SAT was 18.19 (95% CI, 13.70 to 23.67), while the IR was 9.18 (95% CI, 7.72 to 10.84) in the 65 to 69 age group.
Conclusion: SAT could be a potential long-term complication of COVID-19. Long-term surveillance for thyroid dysfunction is needed especially in hospitalized, female and young-aged subjects.

참고문헌 (Reference)

• 1 Lania A, "Thyrotoxicosis in patients with COVID-19 : the THYRCOV study" 183 : 381-387, 2020
• 2 Zhang Y, "Thyroid dysfunction may be associated with poor outcomes in patients with COVID-19" 521 : 111097-, 2021
• 3 Lui DT, "Thyroid dysfunction in relation to immune profile, disease status, and outcome in 191 patients with COVID-19" 106 : e926-e935, 2021
• 4 Frisullo G, "Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate : an Italian multicenter study" 20 : 1265-1268, 2014
• 5 Angum F, "The prevalence of autoimmune disorders in women : a narrative review" 12 : e8094-, 2020
• 6 Domin R, "Subacute thyroiditis : literature overview and COVID-19" 89 : e472-, 2020
• 7 Gu J, "Study on the clinical significance of ACE2 and its age-related expression" 14 : 2873-2882, 2021
• 8 Muller I, "SARS-CoV-2-related atypical thyroiditis" 8 : 739-741, 2020
• 9 Ziegler CG, "SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues" 181 : 1016-1035, 2020
• 10 Giovanella L, "Prevalence of thyroid dysfunction in patients with COVID-19 : a systematic review" 9 : 233-240, 2021
• 11 Yin T, "Prevalence of comorbidity in Chinese patients with COVID-19 : systematic review and meta-analysis of risk factors" 21 : 200-, 2021
• 12 Naguib R, "Potential relationships between COVID-19and the thyroid gland : an update" 50 : 3000605221082898-, 2022
• 13 Chen W, "Potential interaction between SARS-CoV-2 and thyroid : a review" 162 : bqab004-, 2021
• 14 Amenta EM, "Postacute COVID-19 : an overview and approach to classification" 7 : ofaa509-, 2020
• 15 Boaventura P, "Post-COVID-19 condition : where are we now?" 12 : 517-, 2022
• 16 Centers for Disease Control and Prevention, "Post-COVID conditions: CDC science" CDC
• 17 Ladds E, "Persistent symptoms after Covid-19 : qualitative study of 114"long Covid"patients and draft quality principles for services" 20 : 1144-, 2020
• 18 Stasiak M, "New aspects in the pathogenesis and management of subacute thyroiditis" 22 : 1027-1039, 2021
• 19 Kreisler A, "Multiple sclerosis, interferon beta and clinical thyroid dysfunction" 107 : 154-157, 2003
• 20 Gandhi RT, "Mild or moderate COVID-19" 383 : 1757-1766, 2020
• 21 Monzani F, "Long-term interferon beta-1b therapy for MS : is routine thyroid assessment always useful?" 55 : 549-552, 2000
• 22 Korea Disease Control and Prevention Agency, "Long COVID" KDCA
• 23 David Tak Wai Lui ; Chi-Ho Lee ; Wing-Sun Chow ; Alan Chun Hong Lee ; Anthony Raymond Tam ; Carol Ho Yi Fong ; Chun Yiu Law ; Eunice Ka Hong Leung ; Kelvin Kai Wang To ; Kathryn Choon Beng Tan ; Yu-Cho Woo ; Ching Wan Lam ; Ivan Fan Ngai Hung ; Karen Siu Ling Lam, "Insights from a Prospective Follow-up of Thyroid Function and Autoimmunity among COVID-19 Survivors" 대한내분비학회 36 (36): 582-589, 2021
• 24 Yong SJ, "Inflammatory and vascular biomarkers in post-COVID-19 syndrome : a systematic review and metaanalysis of over 20 biomarkers" 33 : e2424-, 2023
• 25 Ahn HY, "Incidence of subacute thyroiditis during the COVID-19 pandemic in South Korea using the National Health Insurance Service Database" 32 : 1299-1306, 2022
• 26 Sunada N, "Hormonal trends in patients suffering from long COVID symptoms" 69 : 1173-1181, 2022
• 27 Lui DT, "Higher SARS-CoV-2 viral loads correlated with smaller thyroid volumes on ultrasound among male COVID-19survivors" 74 : 205-214, 2021
• 28 Lazartigues E, "Endocrine significance of SARS-CoV-2’s reliance on ACE2" 161 : bqaa108-, 2020
• 29 Wang W, "Detection of SARS-CoV-2 in different types of clinical specimens" 323 : 1843-1844, 2020
• 30 Stasiak M, "Clinical characteristics of subacute thyroiditis is different than it used to be : current state based on 15 years own material" 39 : 489-495, 2019
• 31 Boguslawska J, "Cellular and molecular basis of thyroid autoimmunity" 11 : e210024-, 2022
• 32 Brancatella A, "COVID-induced thyroid autoimmunity" 37 : 101742-, 2023
• 33 World Health Organization, "COVID-19 weekly epidemiological update, edition 115, 26 October 2022" WHO
• 34 Duntas LH, "COVID-19 and thyroid diseases : a bidirectional impact" 5 : bvab076-, 2021
• 35 Watad A, "Autoimmune/inflammatory syndrome induced by adjuvants and thyroid autoimmunity" 7 : 150-, 2017
• 36 Darvishi M, "Association of thyroid dysfunction and COVID-19 : a systematic review and meta-analysis" 13 : 947594-, 2022
• 37 Lui DT, "A prospective follow-up on thyroid function, thyroid autoimmunity and long COVID among 250 COVID-19 survivors" 80 : 380-391, 2023